JP5771220B2 - ベクトルイオンチャネルを調節するための有機化合物 - Google Patents

ベクトルイオンチャネルを調節するための有機化合物 Download PDF

Info

Publication number
JP5771220B2
JP5771220B2 JP2012548306A JP2012548306A JP5771220B2 JP 5771220 B2 JP5771220 B2 JP 5771220B2 JP 2012548306 A JP2012548306 A JP 2012548306A JP 2012548306 A JP2012548306 A JP 2012548306A JP 5771220 B2 JP5771220 B2 JP 5771220B2
Authority
JP
Japan
Prior art keywords
amino acid
amino
compound
acid
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012548306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517224A (ja
JP2013517224A5 (enExample
Inventor
フィッシャー，ベルナルド
ルーカス，ルドルフ
ツォツォス，スーザン
Original Assignee
アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー
アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー, アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー filed Critical アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー
Publication of JP2013517224A publication Critical patent/JP2013517224A/ja
Publication of JP2013517224A5 publication Critical patent/JP2013517224A5/ja
Application granted granted Critical
Publication of JP5771220B2 publication Critical patent/JP5771220B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012548306A 2010-01-14 2011-01-12 ベクトルイオンチャネルを調節するための有機化合物 Active JP5771220B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0004110A AT509267A1 (de) 2010-01-14 2010-01-14 Organische verbindungen zur regulierung von vektoriellen ionenkanälen
ATA41/2010 2010-01-14
PCT/AT2011/000014 WO2011085423A1 (de) 2010-01-14 2011-01-12 Zyklische peptide zur regulierung von vektoriellen ionenkanälen

Publications (3)

Publication Number Publication Date
JP2013517224A JP2013517224A (ja) 2013-05-16
JP2013517224A5 JP2013517224A5 (enExample) 2013-10-17
JP5771220B2 true JP5771220B2 (ja) 2015-08-26

Family

ID=43970939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012548306A Active JP5771220B2 (ja) 2010-01-14 2011-01-12 ベクトルイオンチャネルを調節するための有機化合物

Country Status (16)

Country Link
US (1) US8754049B2 (enExample)
EP (1) EP2523968B1 (enExample)
JP (1) JP5771220B2 (enExample)
KR (1) KR101865420B1 (enExample)
CN (1) CN102770442B (enExample)
AT (1) AT509267A1 (enExample)
AU (1) AU2011206907B2 (enExample)
BR (1) BR112012017093A2 (enExample)
CA (1) CA2785185C (enExample)
DK (1) DK2523968T3 (enExample)
ES (1) ES2525381T3 (enExample)
IL (1) IL220924B (enExample)
NZ (1) NZ600818A (enExample)
PL (1) PL2523968T3 (enExample)
RU (1) RU2538597C2 (enExample)
WO (1) WO2011085423A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679239A1 (de) 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
JP6335279B2 (ja) * 2013-04-23 2018-05-30 アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー 式ｘ１−ｇｑｒｅｔｐｅｇａｅａｋｐｗｙ−ｘ２の環状ペプチドを含んでなる医薬組成物および体外肺処置のための使用
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
DK2988768T3 (da) * 2013-04-23 2021-06-21 Apeptico Forschung & Entwicklung Gmbh Lyofilisat indeholdende et cyklisk peptid med Formel X1-GQRETPEGAEAKPWY-X2 til behandling af pulmonære ødemer
WO2015132294A1 (en) * 2014-03-04 2015-09-11 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
CN108025038B (zh) * 2015-09-14 2022-02-01 阿佩普蒂科研究和开发有限责任公司 治疗1b型pha的环状多肽

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968753A (en) * 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
NZ509604A (en) 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema
FR2839514A1 (fr) * 2002-05-07 2003-11-14 Centre Nat Rech Scient Nouveaux peptides cycliques, leur utilisation comme agents anti-microbiens
EP1781323B1 (en) 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
CN101003520A (zh) * 2007-01-12 2007-07-25 陈志龙 一种缬氨酸丁酰联苯化合物
CN101007791A (zh) * 2007-01-12 2007-08-01 东华大学 一种氨基酸联苯化合物
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
CN101298432B (zh) * 2008-05-30 2010-12-22 广州市星业科技发展有限公司 L-吡咯烷酮羧酸钠的制备方法
WO2009149278A1 (en) * 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
DK2397151T3 (en) * 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes

Also Published As

Publication number Publication date
EP2523968A1 (de) 2012-11-21
JP2013517224A (ja) 2013-05-16
EP2523968B1 (de) 2014-09-10
ES2525381T3 (es) 2014-12-23
AU2011206907B2 (en) 2016-06-02
HK1174341A1 (en) 2013-06-07
WO2011085423A1 (de) 2011-07-21
RU2012134322A (ru) 2014-02-20
US20130072444A1 (en) 2013-03-21
CA2785185A1 (en) 2011-07-21
IL220924B (en) 2018-04-30
AT509267A1 (de) 2011-07-15
AU2011206907A1 (en) 2012-06-21
CN102770442B (zh) 2015-09-23
CN102770442A (zh) 2012-11-07
RU2538597C2 (ru) 2015-01-10
BR112012017093A2 (pt) 2016-11-29
NZ600818A (en) 2014-02-28
DK2523968T3 (da) 2014-11-03
PL2523968T3 (pl) 2015-03-31
KR20120134100A (ko) 2012-12-11
CA2785185C (en) 2019-02-19
US8754049B2 (en) 2014-06-17
KR101865420B1 (ko) 2018-07-13

Similar Documents

Publication Publication Date Title
JP3902406B2 (ja) 老化防御効果を示すテトラペプチド、これを基にした薬理学的物質、及びその利用法
JP5771220B2 (ja) ベクトルイオンチャネルを調節するための有機化合物
MX2011008961A (es) Metodo para prevenir y tratar la hiperpermeabilidad.
JP5427186B2 (ja) システイン非含有環状タンパク質
EA011092B1 (ru) Пептид, обладающий стресс-протекторным действием, фармацевтическая композиция на его основе и способ ее применения
KR102217476B1 (ko) 식 ｘ₁－ｇｑｒｅｔｐｅｇａｅａｋｐｗｙ－ｘ₂의 고리 펩티드를 함유하는 동결건조물
US8372799B2 (en) Reverse protein
HK1174341B (en) Cyclic peptides for regulation of vectorial ion channels
HK1142342B (en) Cyclic, cystein-free protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150626

R150 Certificate of patent or registration of utility model

Ref document number: 5771220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250